Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | XL092 |
Synonyms | |
Therapy Description |
Limited information is currently available on XL092 (May, 2019). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XL092 | XL-092|XL 092 | MET Inhibitor 53 VEGFR Inhibitor (Pan) 33 | XL092 is a receptor tyrosine kinase inhibitor that targets MET and other kinases and also prevents angiogenesis through inhibition of VEGF receptor subtypes (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03845166 | Phase I | XL092 | A Study of XL092 in Subjects With Solid Tumors | Recruiting | USA | FRA | ESP | 1 |
NCT05176483 | Phase I | Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) | Recruiting | USA | 0 |